Myriad will launch Precise MRD with select community-based clinicians in March 2026 in breast, followed by colorectal and renal cancers later this year. The company may expand into additional cancer ...

LANSING, Mich., Jan. 16, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today the launch of the new Neogen Molecular Detection Assay ...

Biomarker testing identifies high-risk early-stage NSCLC patients for adjuvant chemotherapy, reducing recurrence risk by 78%. The AIM-HIGH study shows a 96% disease-free survival rate at 24 months ...

LANSING, Mich., April 30, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), a worldwide leader in innovative solutions that help the food and beverage industries ensure safety and quality in ...

Please provide your email address to receive an email when new articles are posted on . A 14-gene molecular assay may help predict adjuvant chemotherapy benefit in early NSCLC. Patients assigned ...

Assay developers in biopharma and research labs strive to save time, reduce costs, and ensure accurate and reproducible results. In quantitative PCR (qPCR) assays, multiplexing—the simultaneous ...

Ultra-rapid digital droplet PCR can measure the levels of tumor cells in a tissue sample in about 15 minutes. (HealthDay News) — Intraoperative ultra-rapid droplet digital polymerase chain reaction ...

This article offers a comprehensive review of the latest diagnostic tools developed for detecting Monkeypox virus (MPXV), especially in light of recent outbreaks. The authors focus on two major ...

With Respiratory Season rapidly approaching the Northern Hemisphere, clinical laboratories must consider diagnostic strategies that produce maximum clinical utility, utilize efficient workflows, and ...

This article and associated images are based on a poster originally authored by Philip Rawlins, James Craswell, Carmina Micelli, Tayo Alleyne-Weir, Andrew Ratcliffe, and Trevor Askwith and presented ...